Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-823-7 | CAS number: 74-94-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Objective of study:
- metabolism
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The objective of the study was to evaluate the metabolism and disposition of DMAB in male Harlan Sprague Dawley (HSD) rats and in in human skin.
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- Further, DMAB was applied in fresh human skin (in vitro)
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- no data
- Route of administration:
- other: oral (gavage), dermal and intravenous
- Vehicle:
- not specified
- Details on exposure:
- no data
- Duration and frequency of treatment / exposure:
- no data
- Dose / conc.:
- 1.5 mg/kg bw/day
- Remarks:
- oral
- Dose / conc.:
- 1.5 mg/kg bw/day
- Remarks:
- intravenous
- Dose / conc.:
- 0.15 mg/kg bw/day
- Remarks:
- dermal
- Dose / conc.:
- 1.5 mg/kg bw/day
- Remarks:
- dermal
- Dose / conc.:
- 15 mg/kg bw/day
- Remarks:
- dermal
- No. of animals per sex per dose / concentration:
- no data
- Control animals:
- not specified
- Positive control reference chemical:
- no data
- Details on study design:
- no data
- Details on dosing and sampling:
- no data
- Statistics:
- no data
- Details on absorption:
- Dermal application:
The absorption of [14C]DMAB following dermal application was moderate; percent dose absorbed increased with the dose, with 23%, 32% and 46% of dose absorbed at 0.15, 1.5 and 15 mg/kg, respectively.
Absorption of DMAB in fresh human skin in vitro was ca. 41% of the applied dose: the analysis of the receptor fluid shows that the intact DMAB complex can be absorbed through the skin. - Details on distribution in tissues:
- Dermal application:
Tissue retention of the radiolabel was low ca. 1%, but was higher than following the gavage or intravenous administration.
Oral/Intravenous application:
After 72 hours, 0.3-0.4% of radioactivity was recovered in tissues. - Details on excretion:
- Oral/intravenous application:
Disposition of radioactivity was similar between gavage and intravenous administration of 1.5 mg/kg [14C] DMAB, with nearly 84%–89% of the administered radioactivity recovered in urine 24 h post dosing. At 72 h, only 1% or less was recovered in feces, 0.3% as CO2, and 0.5%–1.4% as volatiles.
Dermal application:
Urinary and fecal excretion ranged from 18%–37% and 2%–4% of dose, respectively, and 0.1%–0.2% as CO2, and 1%–3% as volatiles - Metabolites identified:
- not specified
- Conclusions:
- In conclusion, the study provides information on the metabolism and disposition of dimethylamine-borane in Harlan Sprague Dawley rats. The disposition of radioactivity was similar between oral and intravenous administration. Tissue retention of the radiolabel was low 1% for dermal application, but higher than the gavage or intravenous administration. For oral, intravenous and dermal application Dimethylamine-borane will be mainly excreted via urine.
- Executive summary:
In a study conducted by the National Toxicology Program, the metabolism and disposition of dimethylamine-borane (DMAB) in male Harlan Sprague Dawley rats and in human skin was evaluated .
Disposition of radioactivity was similar between gavage and intravenous administration of 1.5 mg/kg [14C] DMAB, with nearly 84%–89% of the administered radioactivity recovered in urine 24 h post dosing. At 72 h, only 1% or less was recovered in feces, 0.3% as CO2, and 0.5%–1.4% as volatiles and 0.3%–0.4 % in tissues.
The absorption of [14C]DMAB following dermal application was moderate; percent dose absorbed increased with the dose, with 23%, 32% and 46% of dose absorbed at 0.15, 1.5 and 15 mg/kg, respectively. Urinary and fecal excretion ranged from 18%–37% and 2%–4% of dose, respectively, and 0.1%–0.2% as CO2, and 1%–3% as volatiles. Tissue retention of the radiolabel was low ∼1%, but was higher than following the gavage or intravenous administration.
Following co-administration of DMAB and sodium nitrite by gavage, N-nitrosodimethylamine was not detected in blood or urine above the limit of quantitation of the analytical method of 10 ng/mL.
Absorption of DMAB in fresh human skin in vitro was ∼41% of the applied dose: the analysis of the receptor fluid shows that the intact DMAB complex can be absorbed through the skin.
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- review article
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Objective of study:
- other: Review article about the toxicology of boranes
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Review article
- GLP compliance:
- no
- Radiolabelling:
- no
- Conclusions:
- In conclusion, the review article provides information on the chemistry and elimination of boranes. According to this review paper, dimethylamine borane will be eliminated rapidly in the body.
- Executive summary:
The review article provides information about the toxicology of boranes. In this review article, Roush describes that amine boranes are very stable and hydrolyse very slowly, are selective reducing agents and have variable solubility in water.
It is further reported that dimethylamine borane will be eliminated rapidly in the body. In a study from Levinska, cited by Roush, dimethylamine borane was injected intravenously in a dog. It has been shown that the compound rapidly disappeared from the blood stream, and over 80% was recovered in the urine in the first 24 hours.
Levinskas suggests that the boranes may exert their toxic effects by different metabolic pathways. This approach was suggested by the apparent separation of LD50 for the boranes into two distinct groups based on the milligrams of boron per kilogram rather than on the basis of milligrams of borane per kilogram.
In a study cited from Hill, Levinskas and Merrill, it has been compared the toxicity of the boranes with their reducing power and found that for the known boranes the reducing power paralleled the toxicity considered boranes may interfere with the oxidation-reduction mechanism.
Referenceopen allclose all
Following co-administration of DMAB and sodium nitrite by gavage, N-nitrosodimethylamine was not detected in blood or urine above the limit of quantitation of the analytical method of 10 ng/mL.
Description of key information
In a review paper of Roush, it is described that boranes are very stable and hydrolyse very slowly, are selective reducing agents and have variable solubility in water. Furthermore, dimethylamine-borane will be eliminated rapidly in the body. After intravenous application in the dog, 80% of dimethylamine-borane was recovered in the urine in the first 24 hours.
Moreover, in the publication by Levinskas, the toxicity of several borane compounds was compared by comparing the LD50 values from different routes of administration (oral, inhalative, intraperitoneal) and species (rats and mice). Levinskas suggested, that the boranes may exert their toxic effects by different metabolic pathways. This approach was suggested by the apparent separation of LD50 for the boranes into two distinct groups based on the milligrams of boron per kilogram rather than on the basis of milligrams of borane per kilogram.
A study reported by Mathews et al. provides information on the metabolism and disposition of dimethylamine-borane in Harlan Sprague Dawley rats. Disposition of radioactivity was similar between gavage and intravenous administration of 1.5 mg/kg [14C] DMAB, with nearly 84%–89% of the administered radioactivity recovered in urine 24 h post dosing. At 72 h, only 1% or less was recovered in feces, 0.3% as CO2, and 0.5%–1.4% as volatiles and 0.3%–0.4 % in tissues. The absorption of [14C] DMAB following dermal application was moderate. The percent dose absorbed increased with the applied dose, with 23%, 32% and 46% of dose absorbed at 0.15, 1.5 and 15 mg/kg, respectively. Urinary and fecal excretion ranged from 18%–37% and 2%–4% of dose, respectively, and 0.1%–0.2% as CO2, and 1%–3% as volatiles.
Absorption of DMAB in fresh human skin in vitro was∼41% of the applied dose: the analysis of the receptor fluid shows that the intact DMAB complex can be absorbed through the skin.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
No studies, which were performed according to internationally accepted guidelines (e.g. OECD Test Guideline 417) for evaluation of the toxicokinetics [i.e. Absorption, Distribution, Metabolism and Elimination (ADME)] of dimethylamine-borane, were found in the public domain or in the archives of the applicants. However, existing literature has been identified in the public domain and reviewed for the ADME properties of dimethylamine-borane.
In a review paper of Roush, it is described that Boranes are very stable and hydrolyse very slowly, are selective reducing agents and have variable solubility in water. Further, dimethylamine-borane will be eliminated rapid in the body. After intravenous application in dog, 80% of dimethylamine-borane was recovered in the urine in the first 24 hours.
A rapid elimination has been also seen in a study reported by Mathews et al.. In this study, the metabolism and disposition of dimethylamine-borane in male Harlan Sprague Dawley rats and in human skin was evaluated. Disposition of radioactivity was similar between gavage and intravenous administration of 1.5 mg/kg [14C] DMAB, with nearly 84%–89% of the administered radioactivity recovered in urine 24 h post dosing. At 72 h, only 1% or less was recovered in feces, 0.3% as CO2, and 0.5%–1.4% as volatiles and 0.3%–0.4 % in tissues.
The absorption of [14C] DMAB following dermal application was moderate; percent dose absorbed increased with the dose, with 23%, 32% and 46% of dose absorbed at 0.15, 1.5 and 15 mg/kg bw, respectively. Urinary and fecal excretion ranged from 18%–37% and 2%–4% of dose, respectively, and 0.1%–0.2% as CO2, and 1%–3% as volatiles. Tissue retention of the radiolabel was low ∼1%, but was higher than following the gavage or intravenous administration.
Absorption of DMAB in fresh human skin in vitro was ∼41% of the applied dose: the analysis of the receptor fluid shows that the intact DMAB complex can be absorbed through the skin.
Based on these studies it can be concluded, that oral, intravenous and dermal applied dimethylamine-borane will be eliminated mainly and rapid via urine. A small part will be excreted via feces and low amounts (ca. 1 % or below) will retend in tissues. It has also been shown for dermal application that percent dose absorbed increased with the dose.
Another aspect was shown in a study conducted by Levinskas. Levinskas suggests that the boranes may exert their toxic effects by different metabolic pathways. This approach was suggested by the apparent separation of LD50 for the boranes into two distinct groups based on the milligrams of boron per kilogram rather than on the basis of miligrams of borane per kilogram.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.